trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['1297p', 'prodige-24', ' gem ', 'deliver,(-delivered),(-delivery),(-delivers)', 'biomarker', 'nicol', 'marker ']
 abstract 1297p by nicolle et al validating gempred sig in prodige-24 adjuvant mffx can be difficult to deliver if pts can be biomarker selected for gem approaches in all stages pdac- we can move the needle! 
Medical Oncologist; clinical and translational researcher pancreatic and hepatobiliary cancers. Views are my own